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Abstract: Human eye development is coordinated through an extensive network of genetic signalling
pathways. Disruption of key regulatory genes in the early stages of eye development can result in
aborted eye formation, resulting in an absent eye (anophthalmia) or a small underdeveloped eye
(microphthalmia) phenotype. Anophthalmia and microphthalmia (AM) are part of the same clinical
spectrum and have high genetic heterogeneity, with >90 identified associated genes. By understanding
the roles of these genes in development, including their temporal expression, the phenotypic variation
associated with AM can be better understood, improving diagnosis and management. This review
describes the genetic and structural basis of eye development, focusing on the function of key genes
known to be associated with AM. In addition, we highlight some promising avenues of research
involving multiomic approaches and disease modelling with induced pluripotent stem cell (iPSC)
technology, which will aid in developing novel therapies.
Keywords: anophthalmia; microphthalmia; coloboma; eye; genetics; development; induced
pluripotent stem cells; SOX2; OTX2; genes
1. Introduction
The development of the human eye is a tightly controlled morphogenetic process which requires
precise spatial and temporal gene regulation [1–5]. Perturbation of early eye organogenesis, either due
to genetic or environmental factors, can result in lack of eye induction or abortion of eye development [6].
Anophthalmia and microphthalmia (AM) are, respectively, the absence or reduced size of the ocular
globe compared to the population age-adjusted mean (Figure 1) [7,8]. Both are part of the same
clinical spectrum and, therefore, can overlap, as the phenotype can be difficult to delineate in severe
cases [9,10]. True anophthalmia occurs when eye development is aborted at the stage of the developing
optic vesicle around 3–4 weeks gestation, leading to absence of the eye, optic nerve and chiasm,
which can be confirmed through MRI brain and orbit scans [9]. Frequently, a small cystic remnant
is detectable termed clinical anophthalmia, which occurs when the optic vesicle has formed but
subsequently degenerates, hence a hypoplastic optic nerve, chiasm or tract may be present [10]. In
microphthalmia, the eye has a smaller volume, and can be associated with a reduced corneal diameter
(microcornea defined as a horizontal diameter <9 mm in a newborn and <10 mm in children >2
years) [11]. An axial length of <19 mm at 1 year of age or <21 mm in an adult using ultrasound B-scan
substantiates a diagnosis of microphthalmia, representing ≥2 standard deviations below normal [11].
The estimated prevalence of microphthalmia and anophthalmia is 1 in 7000 and 1 in 30,000 live births,
respectively [12]. The effect on vision is dependent on the severity, size of the eye and associated ocular
malformations [9–11]. AM are considered part of the phenotypic continuum with ocular coloboma, a
structural malformation resulting from incomplete fusion of the optic fissure, and are likely to have the
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same genetic basis [12–15]. Microphthalmia is reported in 3.2%–11.2% of blind children, but despite
this there are no treatment options to improve visual function in microphthalmic patients, with current
management focusing on maximising existing vision and enhancing cosmetic appearance [9,11,16].
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33%–95% of AM occurs alongside additional non-ocular systemic malformations, with 20%–45% of 
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deficiency or alcohol consumption [7,20–23]. The genetic variation is attributable to chromosomal 
and monogenic causes, with over 90 identified associated genes (Table 1). Genetic diagnosis can be 
obtained through molecular testing, such as array comparative genomic hybridisation (aCGH) or 
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AM has high clinical heterogeneity, and is rarely an isolated condition, often associated with
other ocular abnormalities within the icrophthalmic or contralateral eye (complex), such as anterior
segment dysgenesis, ocular col boma, cataract or vitreoretinal dysplasia (Table 1) [11]. Furthermore,
33%–95% of AM occurs alongside additional non-ocular systemic malformations, with 20%–45%
of individuals diagnosed with a recognised syndrome [6,7,10,17–19]. The phenotypic variation
observed with AM may be due to the multitude of genetic variants, including genetic odifiers as
significant intrafamil al variab lity is seen, and/or environment l factors, such as maternal vitamin
A deficiency or alcohol consumption [7,20–23]. The genetic variation is attributable to chromosomal
and monogenic causes, with over 90 identified associated genes (Table 1). Genetic diagnosis can be
obtained through molecular testing, such as array comparative genomic hybridisation (aCGH) or whole
exome/genome sequencing [11]. Identifying the underl ing genetic cause can influence appropriate
disease management with recruitment of the correct multidisciplinary team to screen for potential
syndromic associations, as well as guide genetic counselling and family planning [6,11]. The molecular
diagnosis can be establishe in approximatel 70% f bilateral anophthalmia or severe microphthalmia
cases, but less than 10% f u ilateral cases, which consists of the majority of patients [6,9,11,12].
Through understanding the genetic regulation underlying human eye development, and clarifying
the roles of signalling molecules, we can elucidate how aberrant gene expression results in eye
developmental disorders. Additionally, it is possible to better understand genotype–phenotype
relationships, prognosis and develop new treatments.
2. The Genetic Basis of Human Eye Development
2.1. Eye Field Specification
Human eye development is initiated at three weeks gestation in the anterior neural plate
(Figure 2a) [2,24]. OTX2 is required for the specification of the forebrain, and allows the neural plate to
become competent for eye development by coordinating expression of eye field initiators SIX3, RAX
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and PAX6 [2,3,24–27]. The role of Otx2 in initiating eye development has been shown through animal
studies investigating eye development, which have shown Six3 activates Pax6 and Rx2 expression
in medaka fish, and is sufficient to induce ectopic eyes in the presence of Otx2 in medaka fish and
Xenopus [2,3,24–27]. OTX2 and SOX2 coregulation of RAX, along with SIX3-mediated repression of
WNT allows upregulation of eye field transcription factors (EFTFs), including PAX6, RAX, LHX2,
TBX3 and SIX6 (Figure 2a,b) [1,2,25,28,29]. Rax has been shown to be necessary for inducing eye
development in mice, as Rax knockouts do not form optic structures [29,30]. In Xenopus, Otx2 and Sox2
have been shown to directly synergistically activate Rax through binding to a non-coding sequence
2 kb upstream of the Rax promoter, which is conserved across vertebrates [28]. Furthermore, Sox2
missense mutations identified in patients with ocular disorders were found to disrupt the interaction of
Otx2 and Sox2, as well as Sox2 DNA-binding ability, perturbing the ability of Otx2 and Sox2 to regulate
Rax expression [28]. The role of Six3 in early eye development has been shown in mice, where Six3 is
required for repression of Wnt1 transcription, which is necessary for regionalisation of the forebrain,
as Six3-/- mice show expansion of Wnt1 expression, truncated rostral forebrain and lack eyes [3,31].
EFTFs form a self-regulating network which are sufficient to coordinate the development of the eye
through suppression of genes which antagonise eye development, such as WNT, and upregulation of
genes required for eye development, such as BMP4, demonstrated in Xenopus by the ability of EFTF
RNA cocktails to induce ectopic eye formation [1,2,4,25,32,33]. OTX2 is subsequently downregulated
in the eye field [2,24].
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suppression of genes that antagonize eye development and upregulation of genes required for eye 
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Figure 2. The genetics of early optic vesicle development. (a) A single eye field is induced at the midline
of the anterior neural plate, through OTX2 and SOX2 coregulation of RAX, along with SIX3-mediated
repression of WNT, which allows upregulation of eye field transcription factors (EFTFs) including
PAX6, RAX, LHX2, TBX3 and SIX6. (b) The eye field is formed expressing EFTFs, which form a
self-regulating network sufficient to coordinate the development of the eye through suppression of
genes that antagonize eye development and upregulation of genes required for eye development.
(c) Secretion of factors from TGFβ, FGF and SHH families from the underlying axial mesoderm
stimulate the anterior migration of prospective hypothalamic cells, causing the eye field to split in
two to form bilateral optic primordia. (d) Cellular proliferation and bilateral migration of the optic
primordia is regulated by RAX. (e) The optic primordia evaginate from the forebrain through the
cephalic mesenchyme forming bilateral optic pits/grooves. (f) Extended evagination of the optic pits
through the cephalic mesenchyme results in the formation of bilateral optic vesicles.
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2.2. Splitting of the Eye Field
At 22 days gestation, SIX3-regulated SHH establishes the midline and factors from TGFβ, FGF
and SHH families secreted from the underlying axial mesoderm stimulate the anterior migration of
prospective hypothalamic cells, causing the eye field to split in two (Figure 2c) [1–3,24]. The direct
regulation of Shh by Six3 has been observed in mice, and loss of Shh signalling in mice leads to
defective midline patterning, including cyclopia, also found in humans with mutations in SIX3 and
SHH [1,3,34,35]. Experiments using medaka fish show that FGF signalling is required for neural
patterning to establish a competence region for Shh signalling, and FGFs interact with Shh to activate
downstream targets of Shh required for optic development [2,36]. Ndr2, a member of the TGFβ family,
is required for midline signalling in zebrafish, and loss of Ndr2 expression leads to cyclopia [2,3,37].
Tracking the movement of neural cells in zebrafish has shown that the single eye field is split through
the anterior migration of cells, and cells in Ndr2 mutant zebrafish fail to migrate, resulting in a
single cyclopic eye [2,38]. RAX-positive cells of the eye field proliferate and migrate bilaterally,
resulting in evagination of the optic primordia from the forebrain and the generation of bilateral
optic pits/grooves, observed through fluorescent tagging of Rx3 in wild-type and mutant medaka
fish (Figure 2d,e) [2,4,24,25,30,39,40]. From 22–27 days gestation, further evagination of the optic pits
through the cephalic mesenchyme results in the formation of optic vesicles (Figure 2e,f) [2,3].
2.3. Lens Placode Formation
Within the overlying surface ectoderm, expression of SIX3 directly activates PAX6 and SOX2,
stimulating the formation of a pre-placodal region from 22–27 days gestation (Figure 3a) [4,41–43].
Six3 regulation of the lens pre-placodal region has been demonstrated by conditional deletion of
Six3 in mice, leading to downregulation of Pax6 and loss of Sox2 expression, as well as failure of
the pre-placodal region to thicken [4,42]. Furthermore, ChIP, EMSA and luciferase reporter assays,
show that Six3 activates Pax6 and Sox2 expression in mice [42]. LHX2-regulated BMP4 expression
from the evaginating optic vesicle signals the thickening of the lens placode at day 27–28 of gestation
(Figure 3b) [1,3,4,41,43–45]. The importance of Bmp4 in lens induction has been shown in mouse
models, where homozygous mutant mice lack lenses, but the phenotype can be rescued by exogenous
BMP4 protein [45]. Lhx2 has been shown to regulate Bmp4 expression in the optic vesicle of mice, as
Lhx2-/-mice have downregulated Bmp4 in the optic vesicle, and failure of lens formation [43,46].
2.4. Optic Cup Formation
The developing lens placode releases BMP and retinoic acid which bind to the optic vesicle,
stimulating invagination of the optic vesicle from 31–33 days gestation (Figure 3c,d) [1,4,47–52].
Simultaneously, retinoic acid signalling from the surrounding periocular mesenchyme aids invagination
of the optic vesicle (Figure 3c) [48,51]. Retinoic acid requirement in optic cup formation has been studied
in mouse models, where double knockouts of retinoic acid synthesising retinaldehyde dehydrogenases
developed optic vesicles that failed to invaginate, which were rescued by maternal dietary retinoic
acid administration [1,4,47–52]. Experiments in mice show that filopodia extending mostly from the
lens ectoderm tether the lens to the presumptive retina, allowing coordinated invagination of the
presumptive lens and optic vesicle, and loss of filopodia in mutant mouse models results in reduced
lens pit invagination (Figure 3c–e) [4,53]. In mice and chicks, lens invagination has been shown to occur
through apical constriction, but the mechanisms driving optic vesicle invagination are not entirely clear,
although experiments disrupting the extracellular matrix in chick embryos, alongside computational
investigation have shown the extracellular matrix is required for proper formation and invagination of
the lens placode and optic vesicle, through spatial restriction of proliferating cells [54–57].
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Figure 3. The genetics of optic cup and lens formation. (a) A preplacodal region develops within the
surface ectoderm overlying the optic pit/groove, stimulated by expression of SIX3, which activates
PAX6 and SOX2. (b) The lens placode is signalled to thicken through LHX2-regulated BMP4 expression
from the evaginating optic vesicle. (c) The developing lens placode releases BMP and retinoic acid
(RA), which bind to the optic vesicle, stimulating coordinated invagination of the optic vesicle and lens
placode, which forms the lens pit. (d) The invagination of the optic vesicle results in the formation of
a bilayered optic cup. (e) TGFβ signalling from the extraocular mesenchyme induces and maintains
MITF and OTX2 expression in the outer layer of the optic cup, which forms the presumptive retinal
pigmented epithelium (RPE). FGF signals from the surface ectoderm stimulate the inner layer of the
optic cup to form a VSX2-expressing presumptive neural retina (NR). The continued invagination of
the lens pit results in the formation of the lens vesicle. (f) From 47 days gestation, retinal differentiation
occurs, with the inner layer of the optic cup forming the neural retina (NR) and the outer layer forming
the retinal pigmented epithelium (RPE). The lens vesicle detaches from the surface ectoderm and forms
a definitive lens by 58 days gestation.
The invagination of the optic vesicle results in the formation of a bilayered optic cup
(Figure 3d,e) [33]. TGFβ signalling from the extraocular mesenchyme induces and maintains MITF and
OTX2 expression in the outer layer of the optic cup, which forms the presumptive retinal pigmented
epithelium (RPE), demonstrated experimentally through the removal of the extraocular mesenchyme in
developing chick eyes resulting in absent RPE, which was restored through addition of the TGFβ family
member activin (Figure 3e,f) [4,24,44,58–61]. MITF and OTX2 in the distil optic vesicle activate RPE
differentiation genes, such as QNR71, Tyr, Trp1 and Trp2 in mice [24,62]. Reduction of MITF signalling
in a human embryonic stem cell (hESC) model of eye development disrupted RPE maturation [61].
Additionally, Otx1 and Otx2 mutant mouse models show loss of RPE-specific Mitf expression, and
expansion of neural retina (NR)/optic stalk regions [63]. FGF signals from the surface ectoderm
stimulate the inner layer of the optic cup to form VSX2-expressing presumptive NR, shown in chick
development through Fgf8 localisation to the neural retina, and in vivo application of FGF8, inducing
presumptive chick RPE to differentiate into ectopic NR through preventing expression of RPE marker
Mitf, and inducing NR markers Rx and Sgx1 (Figure 3e,f) [3,4,24,64]. VSX2 in the proximal optic vesicle
represses RPE marker MITF, and is required for cell proliferation [24,65–68]. In Vsx2 mutant mice,
Mitf is ectopically expressed in the NR, indicating Vsx2 represses Mitf expression in the NR [24,68].
Furthermore, mice with impaired Vsx2 production have a small eye phenotype due to decreased
proliferation of retinal progenitor cells [24,69]. PAX6 expression in the presumptive NR maintains
multipotency in retinal progenitor cells, allowing subsequent differentiation into the seven retinal types:
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retinal ganglion cells, horizontal cells, cone photoreceptors, rod photoreceptors, amacrine cells, bipolar
cells and Müller glia [24,70]. Inactivation of Pax6 in mice retinal progenitor cells using conditional
gene targeting restricts the cell fate of retinal progenitor cells to amacrine cells [24,70].
The optic cup is patterned through antagonistic expression of PAX2 and PAX6, shown in mouse
models as Pax6-/- mutants show expansion of the Pax2 expression domain into the optic stalk, and
Pax2-/- mutants show expansion of the Pax6 expression domain into the optic cup, and analysis of the
molecular interactions of Pax6 and Pax2 in mice show reciprocal transcriptional repression [24,32,71,72].
SHH-regulated VAX1/VAX2 expression induces PAX2 expression and represses PAX6 expression in the
proximal optic vesicle, inducing optic stalk formation, demonstrated experimentally by injection of
Shh mRNA into Xenopus embryos, resulting in expansion of the Vax1 and Pax2 domain, at the expense
of the Pax6 domain, in addition to abrogation of Vax1/Vax2 in zebrafish, leading to the expansion of
retinal tissue into the optic nerve territory [24,32,73–75]. The optic fissure forms on the ventral surface
of the optic vesicle from four weeks gestation to enable the hyaloid vasculature to enter and supply the
developing eye with nutrients [76]. This opening fuses by week seven of gestation through apposition
of the epithelial margins around the vasculature, spatial specification along the proximal-distal axis of
the fissure and basement membrane breakdown, resulting in the formation of a continuous epithelial
layer [77–79].
3. The Genetic Basis of Anophthalmia and Microphthalmia
AM has a complex aetiology, with dominant, recessive, autosomal and X-linked inheritance,
although most mutations associated with non-syndromic AM arise de novo sporadic [11,12].
Non-penetrance has been observed, where family members carrying the same variant as the AM
proband exhibit no ocular phenotype, as well as variable expressivity, where relatives with the same
variant exhibit a spectrum of AM and related ocular features [80,81]. Variable expressivity and
non-penetrance may be due to genetic modifiers, and/or stochastic environmental factors which
influence the levels of gene expression [80]. Some cases of AM have been shown to arise through
parental germline mosaicism, where a parent expresses no ocular phenotype as the mutation is not
present in the ocular-derived tissue, but is present in gonadal tissue due to postzygotic mutational
events [10,80,82–84]. This complex pattern of inheritance has implications for providing meaningful
genetic counselling [85]. Chromosomal abnormalities, including aneuploidy, triploidy, translocations,
deletions and duplications account for 20%–30% of AM [9,10,85,86]. Over 90 individual genes are
associated with AM (Table 1), most of which encode transcription factors involved in eye morphogenesis,
or components of the retinoic acid signalling pathway [12,87,88]. Pathogenic monogenic mutations
include missense, nonsense, deletions, insertions and splice-site variants [12,66].
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Table 1. Genes associated with anophthalmia and microphthalmia. A—unilateral or bilateral anophthalmia. M—unilateral or bilateral microphthalmia. I—Isolated
AM with no additional ocular features. C—complex AM (additional ocular features found in microphthalmic or contralateral eye of the patient listed). N—no
syndromic features observed. S—systemic features observed.
Gene Name OMIM# Disease Name DiseaseOMIM#
Anophthalmia/
Microphthalmia
(A/M)
Isolated/Complex (I/C) (Associated Ocular Features) Non-Syndromic/Syndromic (N/S) Reference(s)
1 SOX2 184429 Microphthalmia, syndromic 3(MCOPS3) 206900 A, M
I, C (coloboma, microcornea, iris defect, retinal tuft, optic
nerve hypoplasia, reduced palpebral fissure, congenital
cataract, glaucoma, colobomatous cyst, synechiae,
anterior segment dysgenesis, retinal/chorioretinal
dystrophy, myopia)
N, S [7,10,19,89,90]
2 OTX2 600037 Microphthalmia, syndromic 5(MCOPS5) 610125 A, M
I, C (coloboma, microcornea, retinal defect, optic nerve
hypoplasia/aplasia, small/absent optic chiasm, LCA,
early onset retinal dystrophy, hyperopia, amblyopia,
cataract, focal retinal dysplasia, corectopia, synechiae,
sclerocornea, persistent pupillary membrane, nystagmus,
posterior vitreous opacity)
N, S [7,18,19,21,80,90–93]
3 RAX 601881 Microphthalmia, isolated 3(MCOP3) 611038 A, M
I, C (coloboma, sclerocornea, persistent fetal vasculature,
retinal detachment, optic nerve atrophy/hypoplasia) N, S [7,90,94]
4 VSX2 142993
Microphthalmia, isolated 2
(MCOP2) 610093 A, M
I, C (coloboma, congenital cataract/cloudy cornea, iris
defect, microcornea, no pupillary aperture, retinal
detachment, dislocated lens, small/underdeveloped optic
nerve/chiasm, retinal dysfunction)
N, S [7,66,95]
Microphthalmia, isolated with
coloboma 3 (MCOPCB3) 610092
5 PAX6 607108 Aniridia 1 (AN1) 106210 A, M
I, C (coloboma, aniridia/iris hypoplasia, anterior segment
dysgenesis, agenesis of optic nerve/chiasm, primary
aphakia, sclerocornea, congenital glaucoma)
N, S [7,92]
6 STRA6 610745 Microphthalmia, syndromic 9(MCOPS9) 601186 A, M
I, C (coloboma, cyst, retinal detachment, abnormal
cornea/iris) N, S [19–21,96–98]
7 RARβ 180220 Microphthalmia, syndromic 12(MCOPS12) 615524 A, M
I, C (coloboma, sclerocornea, anterior segment
dysgenesis) S [21,87,88]
8 ALDH1A3 600463 Microphthalmia, isolated 8(MCOP8) 615113 A, M
I, C (coloboma, microcornea corectopia, cyst,
hypoplastic/small optic nerve/tract/chiasm, small/short
palpebral fissure, conjunctival discoloration,
symblepharon, nystagmus, iris attachment to the cornea)
N, S [99–101]
9 FOXE3 601094 Anterior segment dysgenesis 2(ASD2) 610256 M
C (coloboma, anterior segment dysgenesis, sclerocornea,
aphakia, aniridia) N, S [7]
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Table 1. Cont.
Gene Name OMIM# Disease Name DiseaseOMIM#
Anophthalmia/
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Isolated/Complex (I/C) (Associated Ocular Features) Non-Syndromic/Syndromic (N/S) Reference(s)
10 BMP4 112262 Microphthalmia, syndromic 6(MCOPS6) 607932 A, M
I, C (coloboma, microcornea, retinal dystrophy, myopia,
sclerocornea, anterior segment dysgenesis, corectopia,
blepharophimosis, optic nerve hypoplasia,
tilted/anomalous optic disc, cyst, nystagmus, cataract,
glaucoma, aphakia, embryotoxon, persistent hypoplastic
primary vitreous)
N, S [102,103]
11 BMP7 112267 - - A, M I, C (coloboma) S [104]
12 GDF3 606522
Microphthalmia, isolated 7
(MCOP7) 613704 M
I, C (coloboma, optic nerve hypoplasia, foveal
hypoplasia, nystagmus) N, S [105]
Microphthalmia, isolated with
coloboma 6 (MCOPCB6) 613703
13 GDF6 601147
Microphthalmia, isolated 4
(MCOP4) 613094 A, M
I, C (coloboma, optic nerve hypoplasia, foveal
hypoplasia, nystagmus) N, S [7,21,90]
Microphthalmia, isolated with
coloboma 6, digenic (MCOPCB6) 613703
14 ABCB6 605452 Microphthalmia, isolated withcoloboma 7 (MCOPCB7) 614497 M C (coloboma) N [106]
15 ATOH7 609875
Persistent hyperplastic primary
vitreous, autosomal recessive
(PHPVAR)
221900 M
I, C (microcornea, congenital cataract/corneal opacity,
optic nerve aplasia/hypoplasia, retinal
detachment/nonattachment, persistent fetal vasculature,
nystagmus, vitreous degeneration, glaucoma, shallow
anterior chamber, anterior displacement of the iris,
peripheral anterior synechiae, calcifications present on
the hyaloid membranes/retina/vitreous,
vitreoretinal dysplasia)
N [107]
16 C12orf57 615140 Temtamy syndrome (TEMTYS) 218340 M C (coloboma) S [108]
17 TENM3 610083 Microphthalmia, isolated withcoloboma 9 (MCOPCB9) 615145 M
C (coloboma, microcornea, nystagmus, esotropia,
myopia, retinal detachment) N, S [109,110]
18 VAX1 604294 Microphthalmia, syndromic 11(MCOPS11) 614402 A, M C (optic nerve hypoplasia, small optic nerve, cyst) S [111]
19 SMOC1 608488 Microphthalmia with limbanomalies (MLA) 206920 A C (optic nerve/tract aplasia) S [112]
20 FNBP4 615265 Microphthalmia with limbanomalies (MLA) 206920 A I S [113]
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21 SHH 600725 Microphthalmia, isolated withcoloboma 5 (MCOPCB5) 611638 A, M
I, C (coloboma, funnel retinal detachment with
sub-retinal opacity, microcornea, small optic nerve,
retinal dystrophy, tilted optic disc, myopia, nystagmus,
glaucoma, posterior embryotoxon)
N, S [102,114,115]
22 NAA10 300013 Microphthalmia, syndromic 1(MCOPS1) 309800 A I S [116]
23 BCOR 300485 Microphthalmia, syndromic 2(MCOPS2) 300166 A, M
I, C (congenital cataract, microcornea, posterior
embryotoxon, secondary aphakia, secondary glaucoma,
retinal detachment, persistent fetal vasculature, iris
heterochromia, nystagmus, myopia, iris rubeosis, flat
anterior chambers)
S [117]
24 HCCS 300056
Linear skin defects with multiple
congenital anomalies 1
(LSDMCA1)
309801 A, M I, C (corneal opacity/cloudy and vascular cornea, cyst,sclerocornea, glaucoma,) S [118]
25 MAB21L2 604357 Microphthalmia, syndromic 14(MCSKS) 615877 A, M
I, C (coloboma, microcornea, exotropia,
sclerocornea, strabismus) S [119]
26 RBP4 180250 Microphthalmia, isolated withcoloboma 10 (MCOPCB10) 616428 A, M
C (coloboma, small optic nerve/chiasm, cyst,
underdeveloped extraocular muscles) N, S [81,120]
27 GLI2 165230 Holoprosencephaly 9 (HPE9) 610829 A, M I, C (coloboma, optic nerve agenesis) S [121–123]
28 PORCN 300651 Focal dermal hypoplasia (FDH) 305600 A, M I, C (coloboma, aniridia, strabismus, ectopia lentis) S [124,125]
29 FRAS1 607830 Fraser syndrome 1 (FRASRS1) 219000 A, M C (fused/small palpebral fissure, cryptophthalmos) S [126]
30 FREM1 608944 Manitoba oculotrichoanalsyndrome (MOTA) 248450 A I, C (coloboma, obstruction of the nasolacrimal duct) S [127]
31 SMCHD1 614982 Bosma arhinia microphthalmiasyndrome (BAMS) 603457 M
I, C (coloboma, hypertelorism, occluded or absent
nasolacrimal duct, cataract) S [128]
32 SIX6 606326 Microphthalmia, syndromic 6(MCOPS6) 607932 A, M
C (coloboma, cataract, nystagmus, secondary glaucoma,
optic nerve dysplasia/absence of optic nerve/chiasm/tract,
retinal dystrophy, cyst)
S [129]
33 TFAP2A 107580 Branchiooculofacial syndrome(BOFS) 113620 A, M
C (coloboma, cataract/corneal clouding, reduced corneal
diameter, primary aphakia, sclerocornea, retinal
detachment, lacrimal duct obstruction, cyst, subluxed
cataractous lens, shallow anterior chamber, persistent
pupillary membrane, iris hypoplasia, dysplastic
optic disc)
S [130]
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Isolated/Complex (I/C) (Associated Ocular Features) Non-Syndromic/Syndromic (N/S) Reference(s)
34 TCTN2 613846 Meckel syndrome, type 8 (MKS8) 613885 A, M I S [131]
35 CSPP1 611654 Joubert syndrome 21 (JBTS21) 615636 A I S [132]
36 COL4A1 120130 Brain small vessel disease with orwithout ocular anomalies (BSVD1) 175780 M
C (microcornea, Peter’s anomaly, retinal detachment,
congenital cataract, glaucoma, anterior segment
dysgenesis, hypermetropia, astigmatism)
S [133,134]
37 PTCH1 601309 Holoprosencephaly 7 (HPE7) 610828 M C (coloboma, cataract, sclerocornea, anteriorsegment dysgenesis) N, S [135]
38 TBC1D32 615867 Orofaciodigital syndrome IX(OFD9) 258865 A, M C (coloboma) S [136]
39 CHD7 605806 CHARGE syndrome 214800 A, M I, C (coloboma, microcornea, cataract, persistent fetalvasculature) N, S [137–139]
40 MFRP 606227
Microphthalmia, isolated 5
(MCOP5) 611040 M
C (retinitis pigmentosa, foveoschisis, optic disc drusen,
macular edema, glaucoma, hyperopia) N [140]
Nanophthalmos 2 (NN02) 609549
41 PRSS56 613858 Microphthalmia, isolated 6(MCOP6) 613517 M
C (hyperopia, elevated papillomacular retinal fold,
shallow anterior chamber, thick lens, thickened
scleral wall)
N [141,142]
42 TMEM98 615949 Nanophthalmos 4 (NN04) 615972 M
C (hyperopia, angle closure glaucoma, narrow
iridocorneal angle, shallow anterior chamber depth, optic
disc drusen)
N [143,144]
43 HMGB3 300193 Microphthalmia, syndromic 13(MCOPS13) 300915 A, M C (coloboma, congenital cataract) S [145]
44 PXDN 605158 Cornea opacification and otherocular anomalies (ASGD7) 269400 M
C (sclerocornea, anterior segment dysgenesis,
iridocorneal dysgenesis, glaucoma, cataract) N, S [146]
45 TMX3 616102 Microphthalmia with coloboma 1(MCOPCB1) 300345 A, M I, C (coloboma, cyst) N, S [147]
46 YAP1 606608
Coloboma, ocular, with or without
hearing impairment, cleft
lip/palate, and/or mental
retardation (COB1)
120433 A, M I, C (coloboma, extraocular muscle defect, cataract,ectopic pupil) N, S [148]
47 IPO13 610411 - - M C (coloboma, cataract, narrowed palpebral fissure,nystagmus, microcornea) N [149]
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48 PITX3 602669 Cataract 11, multiple types(CTRCT11) 610623 M C (cataract/corneal opacity) S [150]
49 NDP 300658 Norrie disease (ND) 310600 M C (sclerocornea) N [92]
50 MITF 156845 COMMAD syndrome 617306 M C (coloboma, microcornea with pannus, cataract,translucent irides, optic nerve/tract hypoplasia) S [151]
51 FOXC1 601090 - - M C (microcornea, sclerocornea, cyst, myopia, cataract,Rieger anomaly, retinal detachment) N [152]
52 CRPPA 614631
Muscular
dystrophy-dystroglycanopathy
(congenital with brain and eye
anomalies), type A, 7 (MDDGA7)
614643 M C (cataract, optic nerve hypoplasia) S [153]
53 FANCL 608111 Fanconi anemia, complementationgroup L (FANCL) 614083 M C (short upslant palpebral fissure, indiscernible pupil) S [154]
54 SMO 601500 Curry-Jones syndrome (CRJS) 601707 M C (coloboma, unusually shaped pupil) S [155]
55 DOCK6 614194 Adams-Oliver syndrome 2 (AOS2) 614219 M I, C (retinal detachment) S [156]
56 CRYAA 123580 Cataract 9, multiple types(CTRCT9) 604219 M C (congenital cataract) N [157]
57 FOXL2 605597 Blepharophimosis, ptosis andepicanthus inversus (BPES) 110100 M
C (blepharophimosis, ptosis, epicanthus inversus,
telecanthus, strabismus) N, S [158]
58 CRYBA4 123631 Cataract 23, multiple types(CTRCT23) 610425 M C (cataract, enophthalmia) N [159]
59 ERCC6 609413 Cerebrooculofacioskeletalsyndrome 1 (COFS1) 214150 M
C (congenital cataract, short palpebral fissure,
blepharokeratoconjunctivitis) S [160,161]
60 ERCC5 133530 Cerebrooculofacioskeletalsyndrome 3 (COFS3) 616570 M C (cataract) S [162]
61 ERCC1 126380 Cerebrooculofacioskeletalsyndrome 4 (COFS4) 610758 M C (blepharophimosis) S [163]
62 SRD5A3 611715 Congenital disorder ofglycosylation, type 1q (CDG1q) 612379 M C (coloboma, nystagmus, cataract, optic atrophy) S [164]
63 SALL4 607343 Duane-radial ray syndrome(DRRS) 607323 M C (coloboma, optic nerve hypoplasia) S [165]
J. Dev. Biol. 2019, 7, 16 12 of 37
Table 1. Cont.
Gene Name OMIM# Disease Name DiseaseOMIM#
Anophthalmia/
Microphthalmia
(A/M)
Isolated/Complex (I/C) (Associated Ocular Features) Non-Syndromic/Syndromic (N/S) Reference(s)
64 FREM2 608945 Fraser syndrome 2 (FRASRS2) 617666 M C (coloboma, cyst) S [166]
65 RPGRIP1L 610937 Meckel syndrome 5 (MKS5) 611561 M I S [167]
66 SLC25A24 608744 Fontaine progeroid syndrome(FPS) 612289 M I S [168]
67 FAM111A 615292 Gracile bone dysplasia (GCLEB) 602361 M I S [169]
68 SMG9 613176 Heart and brain malformationsyndrome (HBMS) 616920 M I S [170]
69 SIX3 603714 Holoprosencephaly 2 (HPE2) 157170 M C (coloboma, myopia, astigmatism, dysplastic opticnerve, nystagmus, exotropia, cataract, hypertropia) S [171]
70 PDE6D 602676 Joubert syndrome 22 (JBTS22) 615665 M I, C (coloboma) S [172]
71 KMT2D 602113 Kabuki syndrome 1 (KABUK1) 147920 M C (cyst) S [173]
72 PAX2 167409 Papillorenal syndrome (PAPRS) 120330 M C (coloboma, optic nerve dysplasia, retinal degeneration) S [174,175]
73 TMEM216 613277 Meckel syndrome, type 2 (MKS2) 603194 M I S [176]
74 CEP290 610142 Meckel syndrome, type 4 (MKS4) 611134 M I S [177]
75 KIF11 148760
Microcephaly with or without
chorioretinopathy, lymphedema,
or mental retardation (MCLMR)
152950 M
I, C (coloboma, cataract, chorioretinopathy,
hypermetropia, persistent hyaloid artery, peripheral
fibrovascular proliferation, retinal detachment)
S [178,179]
76 SNX3 605930 - - M I S [180]
77 ZEB2 605802 Mowat-Wilson syndrome (MOWS) 235730 M C (cataract, retinal aplasia, corectopia, optic nervehypoplasia/pallor, retinal atrophy) S [181]
78 POMT1 607423
Muscular
dystrophy-dystroglycanopathy
(congenital with brain and eye
anomalies), type A, 1 (MDDGA1)
236670 M
C (anterior chamber dysgenesis, exophthalmia,
buphthalmos, megalocornea, glaucoma, retinal dysplasia,
congenital cataract/corneal clouding, retinal detachment)
S [182,183]
79 POMT2 607439
Muscular
dystrophy-dystroglycanopathy
(congenital with brain and eye
anomalies), type A, 2 (MDDGA2)
613150 M C (Peter’s anomaly, cataract, buphthalmos) S [184]
80 POMGNT1 614828 - - M C (corneal clouding/cataract) S [185]
81 FKTN 607440
Muscular
dystrophy-dystroglycanopathy
(congenital with brain and eye
anomalies), type A, 4 (MDDGA4)
253800 M C (retinal detachment) S [186]
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82 FKRP 606596
Muscular
dystrophy-dystroglycanopathy
(congenital with brain and eye
anomalies), type A, 5 (MDDGA5)
613153 M C (cataract, asymmetric pupils, persistent hyperplasticprimary vitreous, anterior chamber abnormality) S [187,188]
83 DAG1 128239
Muscular
dystrophy-dystroglycanopathy
(congenital with brain and eye
anomalies), type A, 9 (MDDGA9)
616538 M C (buphthalmos, corneal opacity, glaucoma, retinaldetachment) S [189,190]
84 B3GALNT2 610194
Muscular
dystrophy-dystroglycanopathy
(congenital with brain and eye
anomalies, type A, 11 (MDDGA11)
615181 M C (cataract, optic nerve hypoplasia, myopia) S [191]
85 RAB3GAP1 602536 Warburg micro syndrome 1(WARBM1) 600118 M C (microcornea, cataract) S [192]
86 RAB3GAP2 609275
Warburg micro syndrome 2
(WARBM2) 614225 M
C (congenital cataract, small pupil, aphakia,
hypermetropia, secondary glaucoma) S [193,194]
Martsolf syndrome 212720
87 NHS 300457
Nance-Horan syndrome (NHS) 300672
M C (microcornea, congenital cataract) S [195]
Cataract 40, X-linked (CTRCT40) 302200
88 HMX1 142992 Oculoauricular syndrome(OCACS) 612109 M
C (microcornea, coloboma, nystagmus, cataract,
microphakia, synechiae, anterior segment dysgenesis,
small dysplastic optic disc, strabismus, sclerocornea,
posterior embryotoxon, stromal iris cyst, retinal
dystrophy, dysplastic macropapillae, macular hypoplasia,
irido-corneal adherences, enophthalmus, esotropia,
calcified phthisis bulbi)
S [196,197]
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89 GJA1 121014
Oculodentodigital dysplasia,
autosomal recessive 257850 M I, C (cataract, uveitis, glaucoma, persistent
pupillary membrane)
S [198–200]
Oculodentodigital dysplasia
(ODDD) 164200
90 LRP5 603506 Osteoporosis-pseudogliomasyndrome (OPPG) 259770 M
C (retinal detachment, persistent hyperplasia of the
primary vitreous) S [201]
91 PQBP1 300463 Renpenning syndrome (RENS1) 309500 M C (coloboma) S [202]
92 TUBB 191130
Symmetric circumferential skin
creases, congenital, 1 (CSCSC1) 156610 M C (short palpebral fissure, retinal dysplasia, microcornea) S [203,204]
Cortical dysplasia, complex, with
other brain malformations 6
(CDCBM6)
615771 M
93 MAPRE2 605789 Symmetric circumferential skincreases, congenital, 2 (CSCSC2) 616734 M C (short/slanting palpebral fissure, strabismus, ptosis) S [203]
94 SALL1 602218 Townes-Brocks syndrome 1 (TBS1) 107480 A, M C (abnormal lens, aplastic optic nerve, small opticchiasm) S [205]
95 HDAC6 300272
Chondrodysplasia with
platyspondyly, distinctive
brachydactyly, hydrocephaly, and
microphthalmia
300863 M I S [206,207]
96 ALX1 601527 Frontonasal dysplasia 3 (FND3) 613456 M C (coloboma) S [208]
97 RERE 605226
Neurodevelopmental disorder
with or without anomalies of the
brain, eye, or heart (NEDBEH)
616975 M C (coloboma, optic nerve hypoplasia, anisometropia) S [209]
98 RAB18 602207 Warburg micro syndrome 3 614222 M C (microcornea, congenital cataract, small atonic pupil,progressive optic atrophy) S [210]
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There is significant inter- and intra-familial phenotypic variability amongst patients and this
may be related to specific genotype–phenotype correlations, or yet unidentified genetic modifiers.
In PAX6-related ocular disease, haploinsufficiency gives rise to a range of phenotypes; the majority
of loss-of-function alleles result in classic aniridia (with full iris and foveal hypoplasia, nystagmus,
cataract, glaucoma and corneal keratopathy [211]) and missense mutations in the DNA-binding paired
domain result in a milder phenotype, such as dominant nystagmus with foveal hypoplasia and
normal irides [212]. Interestingly, a recent report highlights recurrent missense variants, p.S54R and
p.N124K, associated with severe bilateral microphthalmia, phenocopying SOX2-associated AM [213].
An electromobility gel-shift assay (EMSA) revealed that for p.S54R, an 85% reduction in binding
to the PAX6 protein-responsive element termed the LE9 enhancer was seen compared to wild-type
protein, but with no effect on binding to the SIMO element (an autoregulatory PAX6 binding site
with enhancer activity, resulting in correct maintenance of PAX6 expression). The p.N124K variant
showed a moderate reduction in binding to both DNA enhancer sequences. The precise location of
variants can affect protein function, and the lack of established genotype–phenotype relationships
highlight the need for more correlation studies in disorders with Mendelian inheritance and phenotypic
heterogeneity, such as AM. This will guide clinicians on prognosis and identifying potential therapeutic
targets [85]. Furthermore, exploring the genetic pathways frequently disrupted in AM will support the
identification of novel causative genes, variants, and regulatory elements which may act as genetic
modifiers [85]. The more common genes associated with AM, with evidence from animal and cellular
modelling, will be outlined below. The main genes fall into two distinct categories (i) eye field initiating
transcription factors, such as SOX2, OTX2, RAX, VSX2 and PAX6 or (ii) retinoic acid signalling pathway
components, including STRA6, ALDH1A3 and RARβ [12,87,88].
3.1. Eye Field Initiating Transcription Factors
3.1.1. SOX2
Heterozygous variants of sex-determining region Y-box 2 (SOX2) are the most common known
cause of bilateral anophthalmia and severe microphthalmia, accounting for 15%–40% of cases [8,12,19].
SOX2 mutations are associated with isolated unilateral or bilateral AM, complex AM, and Syndromic
Microphthalmia 3 (MCOPS3), where extraocular features include brain anomalies, neurocognitive
delays, seizures, sensorineural hearing loss, oesophageal atresia, short stature, microcephaly and
genital anomalies (Table 1) [8,12,89]. Over 76 disease-associated variants of SOX2 have been identified,
incorporating loss-of-function deletion, missense, frameshift and nonsense mutations [7,8,12,19].
The majority of AM pathogenic SOX2 mutations arise de novo (60%), but alleles can also be
inherited in an autosomal dominant manner, causing AM due to SOX2 haploinsufficiency [7,8,12,89].
Disease-associated SOX2 variants have been inherited from asymptomatic parents as a result
of mosaicism, such as a case of a mother with no ocular features who had a daughter with
bilateral anophthalmia along with extraocular features of SOX2 syndrome as a result of germinal
mosaicism [83,84]. Consequently, it is important to screen parents for accurate genetic counselling and
future family planning [6,9–11].
SOX2 is a high-mobility group transcription factor [8,28]. In Xenopus, Sox2 and Otx2 have been
shown to function together to coordinate Rax expression in the early eye field [28,29]. Furthermore,
introduction of point mutations in Xenopus Sox2 protein (to replicate missense mutations found
in human ocular abnormalities) resulted in disrupted Rax transactivation and reduced DNA and
Otx2-binding ability of Sox2 [28]. These findings indicate a key role for Sox2 in early eye formation,
through coordinated regulation of EFTF Rax in conjunction with Otx2, and consequently, disruption of
Sox2 results in disrupted eye development through perturbation of the Rax signalling network [28,29].
The severity of ocular abnormalities observed in humans indicate the role of SOX2 may reflect that
of Xenopus, with a conserved key function in transcriptional regulation of key genes in human early
eye development.
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A genotype–phenotype correlation has been suggested for SOX2 mutations in AM cohorts, as
missense mutations, particularly in the DNA-binding or transactivation domains, often result in
non-penetrance or a milder ocular phenotype, such as ocular coloboma, and fewer developmental and
systemic abnormalities, including postnatal growth retardation [8,10,12]. However, a clear correlation
has not been definitively proved [8]. Variable Sox2 ocular phenotypes have been observed in a
gene-dosage allelic series of mouse models, which displayed a range of eye phenotypes where the
severity correlated to the expression of Sox2, suggesting a relationship between SOX2 genotype and
clinical phenotype in humans may exist, due to dosage sensitivity in eye development [10,214].
3.1.2. OTX2
Between 2%–8% of AM cases are estimated to be the result of a pathogenic mutation in OTX2 [8,9,
18,90,91]. Combined, SOX2 and OTX2 variants account for at least 60% of bilateral severe cases of
AM [12,19]. Variants of OTX2 include indel, missense, frameshift and nonsense mutations, and AM is
usually the result of a heterozygous loss-of-function [8,12,19,91]. While 40% of OTX2 mutations arise de
novo, 35% are inherited from an unaffected parent, which complicates inheritance patterns [8,12,19,91].
Frequency of non-penetrance is high, with carrier parents displaying no ocular phenotype, as well as
variable expressivity, for example, a case where one patient displayed unilateral microphthalmia, and his
brother had a right anophthalmic eye and left ocular coloboma [12,18,19,80,91]. This case was believed
to be a result of gonosomal mosaicism, as neither parent was found to carry the mutation in blood or
buccal cell DNA [18]. Mosaicism has been confirmed in other OTX2 cases, such as a patient with bilateral
severe microphthalmia who was the daughter of a phenotypically normal mother shown to have
low levels of the variant in blood and buccal DNA, indicating gonosomal mosaicism [12,18,19,80,91].
OTX2 patients encompass extremely variable phenotypes, including additional eye malformations
such as anterior segment dysgenesis, retinal dystrophy and hypoplasia or aplasia of the optic nerve
and optic chiasm, as well as syndromic features including pituitary abnormalities, hypopituitarism,
brain anomalies, seizures and developmental delay (Table 1) [8,91,93,215]. Homozygous mouse
knockouts of homeobox gene Otx2 lack eyes, while heterozygous knockout mouse models also show a
highly variable phenotype, from acephaly, micrognathia, anophthalmia, microphthalmia to normal
development, depending on the genetic background [8,25,63,80,215–219]. A relationship between
genotype and clinical phenotype has been observed, as mutations in the second half of OTX2 seem
to occur more frequently with abnormal pituitary function, although this correlation is not always
seen [8,91,215].
OTX2 is required for neural development, and coordinates the expression of EFTFs SIX3, RAX
and PAX6 to initiate eye field development, but is subsequently downregulated in the eye field by
EFTFs including RAX [3,25,32,220–222]. Otx2 has been shown to be necessary for eye development in
mouse and Xenopus, as early EFTFs Six3 and Pax6 only possesses the ability to induce ectopic eyes
in the presence of Otx2 expression [25–27,63,223]. Furthermore, overexpression of Otx2 in Xenopus
results in upregulation of Rax, indicating Otx2 is a positive regulator of Rax in early development [28].
OTX2 also plays a role later in eye development, during the regionalisation of the optic vesicle,
where TGFβ signalling from the extraocular mesenchyme induces OTX2 expression in the distil
optic vesicle [24]. WNT signalling then induces upregulation of OTX2 in the prospective RPE [24].
OTX2 is required for RPE maintenance and differentiation, including regulation of key RPE marker
MITF [24,63,224]. Inactivation of Wnt signalling activator β-catenin in mice at the optic vesicle stage
results in a lack of Otx2 and Mitf signalling in the optic cup, and expansion of the NR domain, leading
to anophthalmia [24,59].
3.1.3. RAX
Biallelic mutations in the EFTF RAX are estimated to account for 2%–3% of AM [6,7,11,94].
Disease-associated loss-of-function variants of RAX include missense, nonsense, frameshift and
splicing mutations, as well as whole gene deletions [6,12]. Heterozygous carriers of disease-associated
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variants display no ocular phenotype, indicating an autosomal recessive inheritance pattern [6,7,12].
Homozygous or compound heterozygous RAX variants are often associated with bilateral severe AM,
alongside neurological features such as intellectual deficiency and autism [7].
RAX has been shown to play a conserved role in establishment/proliferation of the eye field,
as expression of ectopic Rax in Xenopus results in formation of ectopic retinal tissue [1,30], and
zebrafish/mouse heterozygous knockouts of Rax have an eyeless phenotype [30,225–227]. The
homeobox gene Rax is expressed early in eye development, and has been identified as necessary
for the initiation of eye field development through regulation by Otx2 and EFTFs Six3 and Pax6 in
targeted mouse knockout models [228]. Rax has been shown in zebrafish to coordinate the splitting
of the eyefield, by downregulating nlcam in the eye field, to decelerate the convergence of retinal
progenitor cells to the midline of the neural plate [39,40]. Overexpression of nlcam results in abnormal
migration of the eye field, converging further towards the midline, resulting in a small eye phenotype
in zebrafish [39]. Furthermore, in chimeric mouse embryos of Rax-/- and wild-type cells, Rax-deficient
cells were not incorporated into optic tissue, indicating a role for Rax in cellular segregation in the
early developing eye [4,29].
3.1.4. VSX2
Biallelic mutations in VSX2 are thought to account for 2% of isolated microphthalmia, and were
identified in 1.5% of all MAC (microphthalmia, anophthalmia and coloboma) cases in a screening
of >880 samples [9,12]. Disease-associated variants include missense, nonsense, exon deletions and
splice-site variants [66,95]. VSX2 has an autosomal recessive inheritance pattern, and homozygous or
compound heterozygous VSX2 variants are usually associated with bilateral AM [12]. VSX2 variants
can result in isolated AM, although complex cases often include cataracts, as well as iris abnormalities,
retinal dystrophy and colobomas, and individual cases with systemic features have been reported,
including developmental delay with behavioural problems, autism, cryptorchidism, ovarian defects,
or hearing impairment, although no genotype–phenotype correlations have been identified [12,17].
VSX2 is a homeodomain-containing transcription factor [95]. Inactivation of the VSX2 orthologue
Alx1 in zebrafish results in small eyes [95,229]. Vsx2 null mice are microphthalmic, and show
reduced proliferation of retinal progenitor cells, as well as transdifferentiation of the neural retina
into RPE [69,95,230,231]. Vsx2 has been shown to regulate retinal cell number via CycD1-mediated
repression of the negative regulator of proliferation cyclin-dependent kinase inhibitor Kip1, in retinal
progenitor cells [231]. Consequently, Vsx2 enables cell proliferation by preventing retinal progenitor
cells from exiting the cell cycle [66,231]. This has been shown as in Vsx2 null mice, Kip1 is abnormally
present in retinal progenitor cells, resulting in cell number decrease in the retina and a small eye
phenotype [231].
In the optic vesicle, VSX2 expression marks the developing neural retina, while MITF is expressed
in the developing RPE [32]. Fgf expression activates Vsx2 in mouse neural retina which represses
Mitf transcription, and Vsx2 null mice show erroneous expression of Mitf in the neural retina [66,68].
Analysis of the function of VSX2 in human iPSC-derived optic vesicles showed WNT to be a downstream
target [232]. Patient-derived iPSCs with a mutation in VSX2 found upregulation of WNT pathway
components and RPE markers, demonstrating VSX2-mediated repression of WNT contributes to
maintaining neural retina identity [232].
3.1.5. PAX6
PAX6 is a transcription factor most commonly associated with aniridia [92,233]. A study of >500
MAC cases found 1%–2% to be PAX6 related [12]. Heterozygous loss-of-function PAX6 variants have
been found in patients with unilateral and bilateral AM, indicating an autosomal dominant inheritance
pattern [7,12,92]. Patients with PAX6-associated microphthalmia often have a complex phenotype,
with associated ocular abnormalities including aniridia, iris hypoplasia, coloboma and optic nerve
hypoplasia (Table 1) [12]. Mosaicism has been reported in PAX6-associated microphthalmia, such as a
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case with two brothers with bilateral complex microphthalmia with a heterozygous missense mutation,
and an unaffected mosaic mother [92].
Missense mutations in the paired-box domain of PAX6 have been more frequently been associated
with MAC, which is the domain known to interact with SOX2 [12,213,234]. The complex formed
by PAX6 and SOX2 is known to be key for initiation of lens development by activation of crystallin
genes [3,234]. Correct formation of the lens is vital to optic cup development, indicating a potential
pathway for PAX6 mutations in the paired-box domain to have an increased likelihood to cause AM.
The homeobox gene PAX6 has been shown to be a conserved regulator of eye development [42,235].
Pax6 mutant mouse models display small eyes alongside other ocular phenotypes [92,236,237]. Pax6-/-
mice develop eyes, but they fail to be maintained, arresting in development prior to the optic cup
stage [2,236–238]. PAX6 is one of the first EFTFs to be expressed, and ectopic expression of Pax6 in
Xenopus can be sufficient to induce ectopic eye tissue [223,235]. Furthermore, misexpression of Pax6 in
Xenopus results in erroneous upregulation of EFTFs including Six3, Rax and Lhx2 [25,223,235]. Pax6
is known to form functional complexes with Lxh2 in mice, which are required for the regulation of
Six6 in the optic vesicle [235,238]. These results indicate PAX6 plays a conserved key role in initial eye
formation by initiating a cascade of gene expression which regulates eye development [223].
Rax-deficient mice show loss of Pax6 expression in the region of the neural plate which would
form the optic primordium, suggesting Rax is an upstream regulator of Pax6 in early eye field
formation [32,228]. In Six3 mutant mice, Pax6 is downregulated in the preplacodal lens ectoderm,
indicating Pax6 in the developing lens is also activated by Six3 [26,42]. Bmp7 has also been implicated
in the initiation of Pax6 in lens induction, as in Bmp7 null mice, Pax6 expression is lost in the lens
placode, resulting in lens defects [3,239].
Moreover, PAX6 is required for the dorso-ventral patterning of the optic cup, where PAX6 is
highly expressed in the dorsal region and PAX2 is expressed in the ventral region [3,235]. In Pax6
mutant mice, there is dorsal expansion of Pax2 expression, while in Pax2 mutants there is ventral
expansion of Pax6, demonstrating the antagonistic function of Pax6 and Pax2 in the optic cup [3,72].
In addition, this patterning is regulated in mice by Shh which promotes ventral expression of Vax1
and Pax2, while inhibiting expression of Pax6 and Rax [24,73,235,240]. In Vax1/Vax2 double-mutant
mice, the optic nerve is transformed into retinal tissue, and Pax6 expression is increased in the ventral
region of the optic cup, demonstrating the importance of Vax1/Vax2 in regulating Pax6 expression
in the optic cup [75]. Lhx2 mutant mouse optic vesicles show lack of downstream target Vsx2 and
display expansion of Pax6 ventrally, indicating Pax6 is partially regulated in the optic cup through
Lhx2-mediated Vsx2 expression [32,46].
3.2. Retinoic Acid Signalling Pathway Components
3.2.1. STRA6
Biallelic loss-of-function mutations in STRA6, including missense, nonsense, frameshift and whole
gene deletions, can lead to AM, usually manifesting bilaterally [8,12,97,241]. Commonly, pathogenic
recessive STRA6 variants result in Microphthalmia, Syndromic 9 (MCOPS9), also known as Matthew
Wood Syndrome, where syndromic features include pulmonary, diaphragmatic and cardiac defects,
resulting in death within the first 2 years of life [12,17,96,242]. However, milder phenotypes have
been observed, including a patient with bilateral anophthalmia and mild syndromic features, in
addition to isolated AM in patients with homozygous missense STRA6 variants [19,20]. However, no
genotype–phenotype correlation has yet been established [8,96,98].
STRA6 is a transmembrane receptor for retinol-binding protein, responsible for mediating vitamin
A uptake into cells [8,20,98,243,244]. Cellular analysis showed that a missense mutation in STRA6
resulted in loss of vitamin A uptake [20]. Furthermore, the clinical phenotype is recapitulated in
zebrafish models, with inhibition of retinoic acid resulting in microphthalmia, and developmental
defects including heart morphogenesis [20]. Patients with STRA6 variants display variation in
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phenotype, such as one family where phenotype ranged from bilateral anophthalmia to unilateral
microphthalmia with contralateral ocular coloboma, indicating phenotypic variation may result from
environmental factors such as variable vitamin A uptake, as well as genetic background [8,20,98].
The severity of phenotypes associated with STRA6 variants demonstrate the importance of
retinoic acid signalling in development [98]. Retinoids can regulate development through enhancing
or suppressing developmental gene expression [20,245,246]. In eye organogenesis, retinoic acid is
required to signal the formation of the lens placode, in addition to the invagination of the optic
vesicle [43,48,49]. Absence of Stra6 in zebrafish impairs retinoic acid receptor signalling and gene
regulation, resulting in craniofacial and cardiac developmental defects, as well as microphthalmia [245].
The results demonstrated in animal and cellular modelling indicate a conserved function of STRA6 in
mediating vitamin A uptake, and that disruption of STRA6 results in AM due to disruption of the
retinoic acid signalling pathway, and consequently, disrupted expression of genes required for eye
development, including lens placode development and optic cup invagination [245].
3.2.2. RARβ
AM is associated with recessive loss-of-function or dominant gain-of-function pathogenic
variants of RARβ [8,21,87,88]. Variants include missense, nonsense and frameshift mutations [87].
Gain-of-function missense RARβ variants found in AM patients were shown to exhibit increased
response to retinoic acid ligands compared to the wild-type, indicating an increase in retinoic acid
signalling mediated by RARβ is sufficient to disrupt eye development [87,88]. The clinical manifestation
of RARβ mutations resemble those of STRA6, including pulmonary and cardiac defects, often resulting
in termination of pregnancy or neonatal death [8,12,87,88].
RARβ is one of three retinoic acid receptors, with RARα and RARγ, which transduce retinoic
acid signalling to allow retinoic acid to regulate specific target genes in development [51,88]. The
retinoic acid receptors form heterodimers which are key to oculogenesis [48,51]. A mouse model with
all three retinoic acid receptors inactivated resulted in clinical anophthalmia, including lack of optic
nerve [51]. In mouse models, Rarβ-mediated retinoic acid signalling in the periocular mesenchyme
has been shown to regulate apoptosis and the expression of Foxc1 and Pitx2, which coordinate the
development of the anterior eye segment [51,247,248].
3.2.3. ALDH1A3
Mutations in the retinaldehyde dehydrogenase gene ALDH1A3 are associated with an
estimated 10% of AM [21,99]. Disease-associated variants include missense, nonsense and exon
skipping [99–101,249]. Biallelic ALDH1A3 mutations tend to be associated with bilateral AM, and
can be isolated or complex (Table 1) [12]. Biallelic pathogenic AM ALDH1A3 alleles are commonly
associated with a neurocognitive phenotype, but additional extraocular findings are rare [8,12,99].
Non-penetrance has been reported with ALDH1A3 disease-associated variants, such as a case of
autosomal recessive ALDH1A3 variants where an asymptomatic sister carried the same homozygous
mutation as two siblings affected with bilateral AM [101,249].
ALDH1A3 is part of the retinoic acid synthesis pathway, through oxidation of retinaldehyde to
retinoic acid [8,48,99]. ALDH1A3 is one of three human retinaldehyde dehydrogenases, which have
specific spatial and temporal expression patterns [48,50,250]. Pax6 mutant rat embryos are deficient in
retinaldehyde dehydrogenase Raldh3 (Human ALDH1A3), indicating Raldh3 is genetically regulated by
key oculogenesis transcription factor Pax6 [48,251].
The mouse retinaldehyde dehydrogenase gene Raldh2 (human ALDH1A2) is expressed in
the periocular mesenchyme [50,250]. Loss-of-function mutations in Raldh2 inhibit optic cup
invagination [49]. Consequently, ALDH1A2 in humans is thought to regulate retinoic acid synthesis
signalling to the invaginating optic vesicle through signalling from the periocular mesenchyme [48].
However, in Raldh1-/-(Human ALDH1A1)/Raldh2-/- mouse embryos, retinoic acid synthesised by Raldh3
in the RPE acts on the neural retina to aid ventral invagination [48,50,250]. Raldh3-/- mouse mutant
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embryos initiate optic cup formation, but lack retinoic acid in the ventral optic cup, resulting in ventral
retina shortening [250,252]. Consequently, there appears to be a conserved role for ALDH1A3 in
synthesis of retinoic acid in the developing ventral optic cup, with mutations resulting in defects in
optic cup formation, including invagination [48,250].
4. Current Research and Future Directions
4.1. Modelling Eye Development Using iPSCs
Current understanding of eye development is heavily based on evidence from animal modelling,
focusing on zebrafish, Xenopus and mouse [76,253,254]. While conserved molecular pathways indicate
a fundamental similarity across vertebrate eye development, conflicting evidence from experiments
performed on different model organisms indicates a degree of divergence in the morphogenesis of the
eye [255,256]. For example, the development of the cornea is known to vary by species; stratification of
the human corneal epithelium occurs early in development, resembling chick development, while the
development of the mouse corneal epithelium does not fully stratify until 10 weeks after birth [255].
Furthermore, the migration of neural crest cells which form the corneal endothelium and stromal
keratocytes occurs in two waves in reptiles, birds and primates, while in rodents, cats, rabbits and cattle,
this occurs in a single wave of cell migration [256]. To comprehensively understand the molecular
basis of human developmental eye defects and ultimately, develop functionally viable therapies, it is
vital to obtain an accurate understanding of human eye development, and appreciate how it differs
from that of model organisms.
One method for understanding human biology is the use of human induced pluripotent stem
cells (hiPSCs) [257,258]. Long-term modelling of hiPSCs can enhance our understanding of normal
human cellular behaviour, as well as better comprehending diseases by deriving patient iPSCs which
can be used for investigating the basis of phenotypic heterogeneity, in addition to therapy screening
and personalised medicine [257,259]. Current work in developing methodologies for organoid
modelling of eye development show potential for gaining a working understanding of human eye
morphogenesis, and developing therapies [259,260]. RNA-seq transcriptome analysis indicates that
stem-cell derived optic cups recapitulate human eye development in vivo, through temporal expression
of cell differentiation markers and retinal disease genes, as well as mRNA alternative splicing [261–263].
Early-stage optic vesicle-like structures generated from hiPSCs derived from a microphthalmic patient
with a VSX2 null variant showed upregulation of WNT pathway components and RPE marker,
MITF, which were rescued by pharmacological inhibition of WNT signalling [232]. These results
showed a key role for VSX2 in WNT signalling and maintenance of the neural retina through WNT
pathway suppression [232]. This study shows the potential utility of hiPSC modelling in improving
understanding of human eye development, and developing novel therapies. However, a constraint of
in vitro modelling is the lack of vasculature and surrounding tissues, which may result in loss of vital
external cues for recapitulating in vivo development [264]. Additionally, whole organism modelling is
necessary for understanding the effect of gene activity on organogenesis of multiple organs, which is
particularly important when studying syndromic disorders [265]. Utilising knowledge gleaned from
in vivo animal modelling in conjunction with human cellular modelling is key to obtaining a complete
picture of the molecular basis of human eye development and the role of perturbed genetic pathways
in congenital disorders, such as AM.
4.2. Genomics and Epigenetics
The functionality and availability of genetic tools has progressed rapidly in recent years.
Next-generation sequencing is a powerful tool for understanding development and disease,
allowing relatively cheap, high-throughput methods for analysing the genome, transcriptome and
epigenome [266]. Whole exome/genome sequencing can identify novel disease-associated coding and
non-coding variants, as well as be a useful tool in diagnosing patients with heterogeneous ocular
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disorders with numerous underlying genetic causes, such as AM (Table 1) [81,267]. Increasing the
proportion of known variants associated with AM will improve the frequency of genetic diagnosis,
which is important for directing disease management, including screening for potential syndromic
features, as well as providing reliable genetic counselling and family planning [11,85]. RNA-seq
has aided in characterising gene expression in the developing retina, as well as elucidating genetic
pathways affected in ocular disorders through differential transcriptomic analysis, such as the role of
VSX2 in regulation of the WNT pathway in retinal organoid differentiation [232,268,269]. Improved
understanding of temporal gene expression throughout eye development will aid in identifying
potential disease-associated variants, as well as putative therapy targets.
A potential source of disruption to the molecular regulation of the developmental pathway is
epigenetic disturbance. Epigenetic changes, such as chromatin remodelling and histone modification,
result in altered gene regulation, and therefore, have a great potential for disrupting the ocular
developmental pathway [270,271]. Heterogeneity in epigenetic patterning in stem cell cultures has
been shown to impact the ability of cells to differentiate into retinae, providing reasonable evidence that
epigenetic regulation is important to normal eye development, and consequentially, may play a role in
ocular malformations [272]. Epigenetic changes altering the secondary structure of DNA have been
shown to induce neurodevelopmental disorders including autism [273]. Utilising epigenetic profiling
techniques such as CHIP-seq to identify epigenetic variation associated with developmental ocular
disorders will provide a better understanding of how these disorders arise, in addition to providing a
new avenue of putative treatments to explore [266,274,275].
4.3. Proteomics and Metabolomics
Post-translational modifications can have a significant impact on protein activity, and consequently,
cellular function, for example, post-translational modifications play a key role in the regulation of
zebrafish retina regeneration [276–278]. Consequently, investigating the proteome alongside the
transcriptome is key to understanding cellular behaviour in eye development. Additionally, the impact
of downstream metabolites in temporal mediation of cellular behaviour has been revealed in recent
years [279]. Advances in metabolomic investigation, such as metabolome profiling, will provide
greater insight into different aspects of cellular processes and how metabolites impact development,
in addition to providing new biomarkers for understanding the pathways disrupted in disease and
targets for neonatal screening therapies [280,281].
4.4. Therapeutics
One of the fundamental reasons for investigating the molecular basis of human eye development
and disease is to manipulate the knowledge gained into targeted therapies that will benefit patients.
As AM is a structural eye defect arising from three weeks gestation, developing prenatal treatments
has been difficult as the mother may not know they are pregnant and compounds may have an
adverse effect on both the mother or the rest of the developing foetus. However, with the first in
utero exploratory multicentre phase I/II clinical trial (NCT03706482) evaluating safety and efficacy of
postnatal or prenatal intravenous administration of allogeneic expanded foetal mesenchymal stem
cells for the treatment of severe osteogenesis imperfecta underway, there may be potential applicability
for congenital ocular disorders in the future.
Small-molecule drugs, such as Ataluren, target in-frame nonsense mutations by interfering with
ribosomal fidelity to enable near-cognate amino acids to be substituted rather than a release factor,
thus enabling the production of full-length functional proteins. This drug had positive results as a
postnatal treatment of aniridia in mouse models, demonstrating developmental plasticity of the eye. A
phase 2 multicentre randomized, double-masked, placebo-controlled clinical trial (NCT02647359) is
currently underway to assess the safety and efficacy of Ataluren for nonsense-mediated aniridia. If
successful, this presents another avenue of post-natal treatment for certain genetic congenital diseases
such as microphthalmia, where growth and visual maturation may be encouraged [282].
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5. Conclusions
This review has highlighted the key molecular coordinators of early-eye development, and
summarized current understanding of how disruption of these precise spatiotemporal regulators can
lead to disruption of eye organogenesis, resulting in anophthalmia or microphthalmia (AM). Recent
advances in the field of genetics, including high-throughput next-generation sequencing technology
has progressed knowledge of the genetic basis of AM, as well as improving diagnosis and genetic
counselling [85]. Increasing genetic screening of AM patients using whole exome/genome sequencing
will continue to improve the rate of diagnosis, through identifying novel disease-associated genes and
isoforms [85]. Furthermore, increased genetic diagnosis will provide larger cohorts to analyse the AM
genotype/phenotype relationship, including identifying environmental factors or genetic modifiers
which may result in heterogeneity and variable expressivity observed in AM [85]. Additionally,
utilising animal and cellular models of AM, in conjunction with genome-editing technology such as
CRISPR, will further advance understanding of function and interactions of molecular regulators of
eye development, and how pathogenic alleles result in AM, with the ultimate aim of creating therapies
that may aid patients with AM [85,232].
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